ISSN: 2169-0111
Massimo Conese
Executive Editor
Associate Professor, Department of Biomedical Sciences
University of Foggia, Italy
Dr. Massimo Conese is currently an Associate Professor at the Department of Biomedical Sciences, University of Foggia, Italy. Dr. Conese obtained his M.D. degree in 1987 and Specialization in Oncology in 1990 from the University of Bari, Italy (field of interest; macrophages and the control of coagulation in health and disease), and his Ph.D. in Cellular and Molecular Biology and Pathology in 1995 from the Second University Medical School, Naples, Italy (field of interest: role of the urokinase/urokinase receptor in pericellular fibrinolysis and cell migration/differentiation). During the Ph.D. program, he spent one year and half in the Institute of Microbiology, Copenhagen, Denmark. Dr. Conese performed postdoctoral research as Research Assistant at the Telethon Institute for Gene Therapy, DIBIT, H. S. Raffaele Scientific Institute, Milan, Italy (1997-2001) and was appointed Group Leader of the Institute for Experimental Treatment of Cystic Fibrosis in the same Institute (2001-2007).
Dr. Massimo Conese is currently an Associate Professor at the Department of Biomedical Sciences, University of Foggia, Italy. Dr. Conese obtained his M.D. degree in 1987 and Specialization in Oncology in 1990 from the University of Bari, Italy (field of interest; macrophages and the control of coagulation in health and disease), and his Ph.D. in Cellular and Molecular Biology and Pathology in 1995 from the Second University Medical School, Naples, Italy (field of interest: role of the urokinase/urokinase receptor in pericellular fibrinolysis and cell migration/differentiation). During the Ph.D. program, he spent one year and half in the Institute of Microbiology, Copenhagen, Denmark. Dr. Conese performed postdoctoral research as Research Assistant at the Telethon Institute for Gene Therapy, DIBIT, H. S. Raffaele Scientific Institute, Milan, Italy (1997-2001) and was appointed Group Leader of the Institute for Experimental Treatment of Cystic Fibrosis in the same Institute (2001-2007).